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Dear Prof. Zanchetti, 
Thank you for your letter of August 1st concerning the manuscript “Endothelial Factors in 
The Pathogenesis and Treatment of Chronic Kidney Disease Part I: General Mechanisms” (JH-D-17-
00735). 
We valued much the Reviewers’ constructive criticisms and implemented all suggested 
changes. To ease their tracking in the revised version the changes made are highlighted in yellow 
in the text.  We believe that after this revision the manuscript has been improved considerably 
and can therefore receive a positive evaluation in the present form. 
Therefore, on behalf of my coworkers, I would like to submit the revised version of for 
consideration for publication in Journal of Hypertension.  
We are grateful for the additional consideration to our work and remain your sincerely. 
 
Kindest regards, 
 
Gian Paolo Rossi, FAHA, FACC 
Clinica dell’Ipertensione  
Department of Medicine – DIMED 
University Hospital 
35128 Padova, Italy 
gianpaolo.rossi@unipd.it 
 
 
Submission letter
Reviewer Comments: 
 
Reviewer #1: 
This is a timely review on an important issue for the high cardiovascular and renal risk of CKD patients. The 
authors' team is composed by internationally respected investigators. 
I have the following suggestions for the authors of this review: 
 
1. The authors have apparently adopted a systematic approach to the review (defined as a "consensus 
statement"). They indeed say ..."we searched the PubMed and Google Scholar databases using a Boolean 
strategy for knowledge generated within these fields over the past decade. Those studies providing important 
novel mechanistic information were selected and incorporated into the current consensus statement." All 
searches made in PubMed and Google are inherently Boolean and therefore the term may be dropped with a 
gain in clarity.  
The authors should rather specify the "search terms" and their combination they adopted for extracting 
pertinent literature. To this scope the authors may consult the PRIMA recommendations for systematic 
reviews by EQUATOR, http://www.prisma-statement.org/documents/PRISMA-P-checklist.pdf . As it is 
customary, the "Search Strategy" can be illustrated into detail in a BOX. 
Even though this referee recognizes that there is an important element of subjectivity in the selection of what 
it is perceived as "novel mechanistic information", a small effort for setting minimal criteria for "novelty" 
would render this review more objective. This is important because as much as 43 papers (out of 110) quoted 
in the review are >10 years older. Furthermore References include over 20 narrative reviews, some of which 
pretty old, which makes difficult for the readers to understand how "novelties" were captured. 
If the authors do not pretend to have done a "systematic review" they may simply qualify their review as a 
narrative, unsystematic review. Also in this case I would suggest that they neatly declare their search strategy 
and the selection process adopted as it is commonly done in (invited) narrative reviews in major journal (for 
example: The Lancet 2016; 388: 285-93). 
 
RE: We appreciated a lot the Reviewer’s criticisms, which helped us in improving the manuscript.  As you 
suggested, we dropped the term ‘Boolean strategy’ because of the huge amount of studies published on the 
endothelium in the last three decades, selection of the articles was indeed a hard task.  As reported in detail 
in the text, after retrieving a great number of articles, we refined our search applying the following criteria: 
a) appropriateness of methodologies; b) novelty; c) relevance for understanding mechanisms and/or clinical 
practice; d) expertise of the authors in the field; e) source of publication.     
Hence, details are now reported in the new paragraph “Methodology and search literature” and MeSH terms 
in Table 1.   
 
2. The Introduction is fairly elaborate and repeats general concepts summarized in several reviews on 
endothelial function (e.g. Circulation. 2012;126:753-67). This introductory part may be easily compacted and 
reduced by the 50% or so, perhaps also quoting the above mentioned Circulation review. 
 
RE: The introduction has been markedly shortened and the Circulation review has been quoted.  
 
 
3. The section focusing on MR interference with endothelial function is inflated (819 words, see also point 3, 
below) as compared to other fundamental sections (1314 words dedicated Endothelin, RAS and NO and the 
interaction of these factors). 
RE: We followed your suggestion of cutting the section on MR by 15%: the revised version now entails 695 
words. 
 
4. One of the most exciting mechanistic novelties about endothelial function of the last decade is the discovery 
that the endothelial glycocalyx acts a negatively charged biopolymer selectively buffering sodium ions 
(Pflugers Arch , 2011, vol. 462 : 519-528 ). This issue is of relevance for the integration of vascular tone, renal 
perfusion and regulation of renal sodium reabsorption in health and disease (Nat Rev Nephrol. 2014;10:146-
Reply to Reviewers
57). The authors quoted 5 papers by Oberleithner related with this issue in the second section (aldosterone 
and the endothelium). This a fundamental mechanism which may deserve to be illustrated into a separate 
subsection also expanding on its potential relevance in the pathophysiology of CKD. 
 
RE: We thank the Reviewer for his/her precious suggestion. We created a new section on glycocalyx, which 
included the effects of aldosterone and the articles suggested by the Reviewer. 
 
 
Reviewer #2: 
The authors have written a very nice review of the pathophysiological implications of the endothelium and 
endothelial dysfunction in renal physiology and renal diseases. The paper is easy to read, well illustrated and 
instructive. 
There are only minor comments to this paper: 
1. In page 6, the authors mention that endothelial function or dysfunction affects the entire vasculature 
including glomeruli and tubuli. Although it is true that tubular function is affected, this is mainly indirectly or 
as an effect on non vascular cells. Tubuli do not belong to the vasculature. The sentence should be modified. 
 
RE: We apologize for the error, which was corrected. 
 
2. When the authors discuss the effects of endothelin antagonists on BP and proteinuria and renal function, 
can they also discuss the potential of the endothelium in mediating the endothelin-antagonists-induced 
peripheral oedema which may occur anywhere in the body and thus are different from calcium channel 
blockers-induced edema. Is there a link with endothelial function? 
 
RE: We thank for the suggestion.  We added a comment on the edema-associated ETA receptor blockade, 
which is deemed to be caused mostly by ETB receptor activation. 
 
3. Another characteristic of CKD and vasculature is vascular rarefaction which has been shown in the skin but 
also within the kidney. Can the authors discuss the potential role of the endothelium in this vascular 
rarefaction? 
 
RE: It is well known that tubulointerstitial fibrosis is associated with capillary rarefaction in CKD.  In mice 
ablation of exon 4 in endothelial Sirt1 gene, which codes for sirtuin 1 (SIRT1), an NAD+-dependent deacetylase 
controlling growth and senescence, impairs endothelium-dependent vasorelaxation and enhances Notch1 
signalling, blunting angiogenesis (Kida et al. BBRC 2016; Vasko et al. JASN 2014). Hence, a link between 
capillary rarefaction and endothelium exists, but if and what endothelial factor(s) affect(s) capillary 
rarefaction is totally unknown.  Although of great interest, because of the limited space, we decided to not 
include such information.  
 
At last, some coauthors are members of the ESH Working Group on the Kidney. It is a pity that this working 
group was not involved in this very nice work 
RE: We fully understand this regret but there are at least four distinguished Nephrologists in our WG, which 
are part of the WG that the Reviewer mentioned.  
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Condensed abstract 
Dysfunction and/or loss of the endothelium in the renal glomeruli and tubular interstitium progressively 
lead to chronic kidney disease.  In this consensus statement the Working Group on Endothelin and 
Endothelial Factors of the European Society of Hypertension and the Japanese Society of Hypertension 
critically review knowledge on the mechanisms underlying endothelial cell injury. In Part I we examine the 
mechanisms by which endothelial factors induce vascular remodeling and the role of different players, 
including endothelin-1, the renin-angiotensin-aldosterone system and their interactions, and of oxidative 
stress.  In Part II we discuss the endothelial dysfunction in the major conditions that affect the kidney. 
 
Condensed abstract
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Abstract 
Kidney damage is a common consequence of arterial hypertension, but is also a cause of atherogenesis.  
Dysfunction and/or harm of the endothelium in glomeruli and tubular interstitium damage the function of 
these structures and translates into dynamic changes of filtration fraction, with progressive reduction in 
glomerular filtration rate, expansion of extracellular fluid volume, abnormal ion balance and hypoxia, 
ultimately leading to chronic kidney disease.  Considering the key role played by endothelial dysfunction in 
chronic kidney disease, the Working Group on Endothelin and Endothelial Factors of the European Society 
of Hypertension and the Japanese Society of Hypertension have critically reviewed available knowledge 
on the mechanisms underlying endothelial cell injury.  This resulted into two manuscripts: in the first we 
herein examine the mechanisms by which endothelial factors induce vascular remodeling and the role of 
different players, including endothelin-1, the renin-angiotensin-aldosterone system and their interactions, 
and of oxidative stress; in the second we discuss the role of endothelial dysfunction in the major 
conditions that affect the kidney. 
 
Key Words: artery; atherosclerosis; blood pressure; diabetes mellitus; endothelin; endothelium; 
hypertension; kidney; nitric oxide; renal failure. 
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1. Introduction 
Arterial hypertension is the most prevalent modifiable cardiovascular (CV) disease risk factor and 
contributes significantly to global disease burden [1,2].  It is often associated with chronic kidney disease 
(CKD), which is also an independent risk factor for atherogenesis [3], an important determinant of overall 
CV risk [4,5].  Renal vasoconstriction and/or impaired Na+ excretion are hallmarks of the early stages of 
both hypertension and CKD, thus implicating a key role for the kidney in the development of 
hypertension.  CKD patients are at increased risk of hypertension, coronary artery disease and stroke, 
which are all major causes of death in these patients even before the development of end-stage renal 
disease [6].  Thus, the CKD is both a cause and consequence of hypertension [7]. 
For decades the endothelium was regarded as an inactive layer lining the vessels [8].  However, after the 
pioneering work of many investigators, including the Nobel laureates Robert Furchgott [9], Louis Ignarro 
and Ferid Murad, who discovered endothelium-derived vasodilating factor nitric oxide (NO)[10], Paul 
Vanhoutte and Jo de Mey [11] who described endothelium-dependent vasoconstriction then 
characterized by Hickey et al. [12], and the discoverers of endothelin-1 (ET-1) Masashi Yanagisawa and 
Tomoh Masaki [13], it became clear that the endothelium is key for the preservation of vascular integrity.  
In  effect, with a weight in an adult man similar to that of the liver and a surface area throughout the body 
comparable to that of four tennis courts, it represents the largest organ in the body [8].   
Impaired endothelium-dependent vasodilation is a hallmark of many CV disease risk factors and 
conditions besides hypertension, suggesting that it can be an early mechanism leading to CV damage or, 
alternatively, a marker of it [14].  Endothelial dysfunction, which involves the entire vascular tree and 
implies a shift towards a pro-inflammatory pro-thrombotic state [15], also affects the renal vasculature.  
Given the specific function of glomerules and tubules (e.g. plasma ultrafiltration, ion reabsorption and cell 
acidification), endothelial loss and/or dysfunction translates into dynamic changes of filtration fraction, 
resulting in a progressive reduction in the glomerular filtration rate (GFR), extracellular fluid volume 
expansion, abnormal ion balance and renal hypoxia, all of which ultimately lead to CKD. 
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Recognizing the key roles played by the endothelium in cardio-renal health, as well as the lack of up to 
date information on its role in CKD, the Working Group on Endothelin and Endothelial Factors of the 
European Society of Hypertension (ESH) in conjunction with the Japanese Society of Hypertension (JSH) 
prepared this consensus document to summarize current knowledge of the mechanisms underlying 
endothelial cell injury and its role in renal damage in arterial hypertension, diabetes mellitus, 
preeclampsia, kidney transplantation, and cancer patients undergoing antiangiogenic therapy.  Part I is 
focused on the general mechanisms underlying endothelial dysfuntion in the kidney; Part II will discuss 
the role of endothelium in CV and metabolic diseases. 
Methodology and literature search.  Each section was assigned to one or two Authors, who were 
responsible for the initial search and selection of the retrieved articles.  Each Author searched the 
PubMed and Google Scholar databases (http://libguides.mit.edu/c.php?g=175963&p=1158594) for 
knowledge generated within these fields over the past decade using the MeSH terms reported in 
Supplemental Table 1.  Only papers written in English language were considered.  Besides the articles 
identified by such strategy, the reference lists of previous reviews published on this topic were examined.  
Seminal papers, even though published more than one decade ago, or review articles were quoted if 
considered fundamental for the present review.  Criteria used for selection of the retrieved articles were 
a) appropriateness of methodologies; b) novelty; c) relevance for understanding mechanisms and/or for 
clinical practice; d) expertise of the authors in the field; e) source of publication.  Then, to offer a coherent 
narrative rather than a descriptive review, the manuscript was reviewed by each other Author, who also 
critically evaluated literature.  A thematic cross-disciplinary (internal medicine, nephrology, pharmacy) 
approach was chosen to avoid a bias towards a specific discipline. 
2. Endothelium-dependent mechanisms and kidney injury 
Mechanical stress, hypoxia, aging, smoking, hypercholesterolemia, diabetes mellitus, and 
hyperhomocysteinemia all lead to an increased formation of reactive oxygen species (ROS), which 
inactivate NO and increase the formation of vasoconstricting and mitogenic substances. This results in an 
imbalance between vasodilating and vasoconstricting endothelial factors (Figure 1).  A decreased 
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bioavailability of NO and/or an increased release of NO inhibitors, such as asymmetric dimethylarginine 
(ADMA), reduce NO bioactivity on the renal vascular smooth muscle cells (VSMC) blunting vasodilation 
(Figure 1)[16–18].  A reduced release of endothelium-derived hyperpolarizing factors (EDHF) (like 
epoxyeicosatrienoic acids) reduces K+ channels activity, and promotes Ca2+ influx, thus activating VSMC 
contraction (Figure 1).  When the release of the vasodilators NO and EDHF is blunted, angiotensin II (Ang 
II) and ET-1 act unopposed to induce renal and systemic vasoconstriction. This leads to reduced renal 
blood flow and hypoxia, with ensuing activation of the renin-angiotensin-aldosterone system (RAAS)[19].  
The negative feedback mechanism whereby Ang II suppresses renin release might modulate this RAAS 
activation, but the effectiveness of this counter-regulation in different clinical settings is far from 
established. 
Moreover, hypoxia inhibits NO synthesis and facilitates formation of hypoxia-inducible factor-1 (HIF-1) 
and ROS, which, via inflammatory nitric oxide synthase (iNOS), promote generation of large amounts of 
NO in leukocytes, VSMCs, and epithelial tubular cells. This gives rise to the formation of peroxynitrite, 
which aggravates microcirculatory dysfunction [20], and possibly also to destabilization of atherosclerotic 
plaques, as peroxynitrite activates matrix metalloproteinases (Figure 1)[21]. 
The production of the potent vasoconstrictor ET-1 is triggered by multiple stimuli, including Ang II, ROS, 
and pro-inflammatory cytokines [22].  Under pathophysiological conditions, this can take place in renal 
cells other than the endothelial cells, including podocytes, epithelial and mesangial cells [23](Figure 2).  
Endothelial cells secrete ET-1 predominantly towards the abluminal side, where ETA and ETB receptors 
(under disease conditions) are located, thereby triggering vasoconstriction and cell proliferation.  Thus, 
ET-1 induces contraction and growth by acting in a paracrine fashion on VSMCs.  ET-1 also releases NO 
and prostacyclin by acting in an autocrine fashion on the ETB subtypes of endothelial cells [24].  
In the kidney ET-1 increases renal vascular resistance and reduces glomerular filtration rate, but also 
water and Na+ absorption in the collecting duct mostly via activation of ETB receptors; ETB also mediate ET-
1 clearance, which may occur in the kidney [25].  Excess ET-1 disrupts the actin cytoskeleton in the 
glomeruli via ETA receptors, favoring proteinuria, glomerulosclerosis, and apoptosis of tubular epithelial 
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cell with ensuing hypoxia and inflammation [26–28]. 
3. Aldosterone-mediated impairment of endothelium-dependent vasodilation 
Aldosterone is produced by the adrenocortical zona glomerulosa and to a lesser extent locally by vascular 
endothelial and smooth muscle cells, mesangial cells, and cardiomyocytes [29–35].  By acting via nuclear 
and cytoplasmic mineralocorticoid receptors [36,37], it regulates vascular tone and vascular, myocardial 
and renal structure.  Mineralocorticoid receptor activation induces both vasoconstriction and 
vasodilation.  The latter involves phosphatidyl-inositol 3 (PIP3) kinase dependent activation of NOS in the 
endothelial cells, a rapid effect that is held to be non-genomic because it is insensitive to inhibitors of 
gene transcription or protein synthesis [38–41].  Thus, the rapid nongenomic effects are crucially 
regulated by the endothelial (dys)function: if endothelial function is intact aldosterone exerts 
vasodilatation and increase GFR, whereas when the endothelial function is impaired with blunted 
endothelial NOS (eNOS) activity, aldosterone causes vasoconstriction, decreased renal plasma flow and 
increased renal vascular resistance [39,41].  The vasoconstricting effect, even in both afferent and efferent 
arterioles, is more pronounced in the efferent arteriole [39]. 
Recent evidence suggests that some effects of aldosterone involve a cross-talk between the 
mineralocorticoid receptor and the G protein-coupled estrogen receptor (GPER)[42][37].  When infused 
into dogs, in which renal perfusion pressure was clamped to 19 mmHg, aldosterone [14 g/kg/day] was 
found to cause hyperfiltration [43].  This finding can explain the hyperfiltration seen in human primary 
aldosteronism, and the apparent worsening of eGFR after cure of the hyperaldosteronism with 
adrenalectomy [44]; however, the correction of hypervolemia after adrenalectomy may also play a role. 
A mineralocorticoid receptor-mediated aldosterone-induced vasoconstriction has been observed in 
healthy humans in the forearm [38].  However, if co-infused with the inhibitor of endothelial NOS (eNOS) 
N(G) monomethyl-L-arginine (L-NMMA), aldosterone [500 g i.v.] increases renal vascular resistance, with 
a more pronounced effect on the afferent than the efferent arteriole [41].  Aldosterone regulates Na+ 
channels in the endothelium, as it does in the distal tubular epithelial cells and collecting duct [45], and 
causes endothelial cell swelling, an effect abolished by the ENaC blocker amiloride [46].  It also increases 
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ENaC, a target of aldosterone in distal tubular epithelial cells (see above) and promotes its insertion to the 
membrane [47] via both genomic and non-genomic effects [45,47–49].   
Mice with a specific knock-out of the mineralocorticoid receptor in endothelial cells alone represent an 
optimal model to investigate the role of this receptor.  In this model a pronounced vasoconstriction was 
found in coronary but not mesenteric arterioles after exposure to ET-1, despite no change in blood 
pressure (BP) or renal Na+ handling [50].  Whether endothelial mineralocorticoid regulates renal 
hemodynamics remains unclear.  However, mice with targeted deletion of mineralocorticoid receptors in 
vascular smooth muscle, or in endothelial cells, show that only the receptor in the former cells is crucial 
for the hemodynamic alterations that lead to acute kidney injury induced by subcutaneous cyclosporine 
administration.  Hence, aldosterone, via the mineralocorticoid receptor, promotes microvascular 
contraction, thereby potentiating the effect of cyclosporine-induced NO deficiency [51]. 
Furthermore, in the model of acute kidney injury induced by pedicle clamping, the ischemic injury was 
prevented by antagonizing the mineralocorticoid receptor [52].  Ischemia-induced oxidative stress and 
cysteine sulfenic acid modification of endothelial cell ETB receptors causing blunted activation of eNOS, 
were prevented by the mineralocorticoid receptor antagonist [52].  
In endothelial cells, aldosterone can also increase the expression of F-actin myofilaments, which, 
combined to G-actin myofilaments, form a web beneath the membrane that dynamically regulates the 
lumen caliber [46].  An increased F-to-G-actin myofilament ratio leads to web polymerization with ensuing 
cell ‘stiffening’ and decreased NO production [46].  Hence, aldosterone may potently cause renal 
vasoconstrictor acting via both endothelium stiffening and decreased NO bioactivity.  Both Ang II, via Ang 
II type 1 (AT1) receptors, and endothelin-1, via ETA receptors, mediate the effects of aldosterone infusion 
on blood pressure and end-organ injury [53,54].  T-lymphocytes have also been implicated in aldosterone-
mediated effects [55].  Of note, human primary aldosteronism is associated with microalbuminuria, a 
marker of early endothelial dysfunction, which persists even after correction of hyperfiltration [56], but 
regresses when primary aldosteronism is cured with adrenalectomy [57]. 
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4. Endothelin-1 (ET-1) in hypertension and renal damage 
ET-1 contributes to the regulation of vascular tone and blood pressure (BP) [58], and to a multitude of 
other physiological processes, including cell proliferation, endothelial dysfunction, arterial stiffness, 
cardiac hypertrophy and tissue fibrosis via epithelial to mesenchymal transition (EMT), and also turns on 
aldosterone secretion, all of which contribute to the development and maintenance of hypertension and 
its detrimental consequences [59,60].  Vascular production of ET-1 is increased in most salt-sensitive 
animal models of hypertension [61].  Notably, the pressor effects of ET-1 appear to be, at least in part, 
dependent on salt, as chronic infusion of a subpressor dose of ET-1 increases BP only when combined with 
a normal or high sodium diet [62].   
By inducing vasoconstriction, vascular remodeling, and decreasing arterial compliance, ET-1 enhances 
arterial pulse wave reflection and central pressure augmentation, contributing to arterial stiffning, 
resulting in a reduced capacity of buffering pressure and pulsatile flow oscillations [63].  Arterial stiffness 
is independently associated with mortality in end-stage renal disease (ESRD) patients, and, moreover, 
worsens rapidly over time in those in hemodialysis [64].  Moreover, infusion of ET-1 in healthy humans to 
increase plasma levels to those seen in ESRD was found to be associated with significant increases in pulse 
wave velocity, central systolic pressure and pulse pressure [65].  
In experimental models of hypertension associated with an increase in ET-1, both selective ETA and non-
selective ETA/B receptor antagonists effectively reduce BP [62].  Importantly, selective ETA receptor 
blockade prevents endothelial cell dysfunction, vascular hypertrophy, and glomerular sclerosis in salt-
dependent genetic hypertension, even when high blood pressure is not fully corrected, suggesting blood 
pressure-independent beneficial effects of the treatment [60,66–68]. 
In hypertensive patients circulating ET-1 levels were found to be increased compared to healthy 
individuals in some, but not all, reports [69].  According to studies with ET receptor antagonists (ERAs) 
both selective and non selective ERAs increase forearm vasodilation and reduce BP more in hypertensive 
patients than in healthy individuals [69].  Finally, even though several chronic studies have suggested that 
both ETA-selective and non-selective ETA/B ERAs can reduce BP [69], no direct head-to-head comparison of 
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the two approaches is available.  In CKD plasma ET-1 is increased [70], likely because of augmented 
production and reduced clearance.  Notably, urinary excretion of ET-1, reflecting renal production, 
increases as renal function declines [70], suggesting that this over activation of the renal ET system 
contributes to hypertension and to worsening of renal function.  
In hypertensive non-diabetic CKD patients acute ETA receptor blockade reduces BP by about 10 mmHg 
[71], a decrease that is attenuated by concomitant ETB receptor antagonism [72], suggesting that 
vasoconstrictor ETB receptor activity is less important than ETB  vasodilatory and ET-1 clearance function, 
at least in this condition.  In a similar patient population, chronic ETA receptor antagonism also reduces BP, 
albeit to a lesser extent [73].  Interestingly, in both acute and chronic studies [71,73] the majority of the 
patients studied were already taking Ang I converting enzyme (ACE) inhibitors, which is important 
clinically because after the publication of the RENAAL, IRMA-1 and IRMA-2 studies [74–76],  CKD patients 
are generally prescribed RAAS inhibitors, not only for BP control but also for their microalbuminuria 
lowering effects.  Limited data with non-selective ETA/B antagonism suggest that this approach may also be 
beneficial in lowering BP in non-diabetic CKD patients [77].  Proteinuria, a manifestation of dysfunction of 
the glomerular filtration barrier, and podocyte injury, a marker of glomerular hypertension, are associated 
with increased CV risk.  Both acute [71,78] and chronic [73] selective ETA receptor blockade and non-
selective ETA/B antagonism [77] reduce proteinuria in patients with non-diabetic CKD.  In the acute studies 
these beneficial effects were abolished by concomitant ETB receptor antagonism [78], suggesting that they 
involve ETB receptor activation.  ETB receptors are also deemed to be responsible for the fluid retention 
and increased vascular permeability, leading to edema, an effect commonly observed after ETA receptor 
blockade possibly resulting from ETB receptor acivation [79].   
The mechanisms underlying proteinuria and its reduction by AT1 receptor blockers (ARBs), ACE inhibitors, 
and ERAs will be discussed in Part II. 
High blood pressure favours heart failure and CKD, which in turn leads to hypertension and CV disease.  
Hence, there is a relationship between the heart and the kidney, usually referred to, albeit improperly 
because the underlying pathophysiology is not clearly known, as “cardiorenal syndrome”.  Endothelial 
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dysfunction occurs in both heart failure and CKD, but whether it is amplified in the cardiorenal syndrome 
remains to be elucidated [80].  
5. Endothelial Glycocalyx  
The endothelial cell surface is coated with proteoglycans covalently bound to polysaccharide chains 
synthesized in the endothelial cells [81].  Sulfation of its components, mostly heparan and chondroitin 
sulfates, makes the glycocalyx a negatively charged gel-like surface.  The endothelial glycocalyx provides a 
passive barrier to water and solute transport, which regulates vascular permeability, and the interaction 
between endothelial and circulating cells, as leukocyte [81].  In the kidney the densely packed hyaluronan 
in the glycocalyx, by anchoring to the glomerular basement membrane, fills the fenestrae of endothelium 
[82], thus preventing filtration of albumin [83], which is close in size to that of the spaces between the 
glycosaminoglycan fibres (for a rev. see [84]).  
Factors that injury endothelium also induce sulfation and deacetylation of heparan sulfate in the 
glycocalyx, increase the expression of glycoproteins, as selectins and integrins, and activate enzymes, as 
heparanase and hyaluronidase II that degrade the glycocalyx [85,86].  The increased heparanase activity 
found in diabetic nephropathy [87,88], alongside the prevention of renal damage in heparanase KO mice 
[84] supports a protective role of the glycocalix in diabetic nephropathy.  Moreover, endothelium-derived 
factors, as ET-1, can activate heparanase in podocytes, with loss of the glycocalix.  The evidence that 
podocyte-specific knockout of both ETA and ETB receptor subtypes in mice prevented the reduction of 
heparan sulfate and endothelial glycocalyx thickness, and the development of proteinuria, supports the 
harmful role of ET-1 for glycocalix [87]. 
Excess aldosterone can also affect glycocalyx by enhancing Na+ binding to glycocalyx, thus saturating its 
negative surface charges and increasing adhesion of red blood cells, an effect that can be preventd by 
spironolactone [46].  Hence, aldosterone not only renders the endothelial cells stiffer (see above section 
3), but also sticker, finally leading to endothelial damage and vasoconstriction [89].   
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6. Interactions between the RAAS, ET-1, and NO in the kidney 
The RAAS, ET-1 and NO interact in a complex fashion (Figure 3)[90]: Ang II was shown to stimulate the 
expression or release of ET-1 in endothelial cells in vitro, and to increase ET-1 production in the kidney 
[22,91].  It also up-regulates the expression of the ETA receptor [92] and the binding of ET-1 to this 
receptor in endothelial cells in vitro [93], and in the kidney in vivo.  In contrast to Ang II, which whilst 
constricting all intra-renal vessels has its most prominent effects on the post-glomerular vessels, ET-1 
causes mainly pre-glomerular constriction (Figure 4)[62].  Further actions of the two peptides that occur in 
parallel in the kidney are mesangial cell contraction, extracellular matrix production, and enhanced 
tubular Na+ absorption (ET-1 stimulates sodium excretion via stimulation of the ETB receptor in proximal 
tubules, see above), an effect that can be enhanced by the secretagogue actions of both peptides on 
aldosterone [94].  
In transgenic animals overexpressing renin with fulminant Ang II-dependent hypertension, ET-1 was 
shown to promote renal fibrosis by activating endothelial-to-mesenchymal transition (EMT)[95], a process 
by which endothelial cells lose their markers and acquire those of mesenchymal cells, thus transforming 
into collagen producing myofibroblasts [96].  This process leads to microvascular rarefaction and fibrosis, 
with consequent hypoxia that threatens endothelial cell repair and regeneration [72].  
Glomerular endothelial cell crosstalk with parietal and glomerular epithelial cells (i.e. the epithelial cells 
that constitute the outer part of the Bowman’s capsule and the podocytes, respectively), which release 
ET-1, Ang II, ROS, cytokines, and other stress-signaling molecules, thus amplifying the injury [97,98].  
Figure 3 summarizes this cross-talk and Figure 2 shows the role of ET-1 in this process (Fig 2 from [98]).   
An injured endothelium drives innate immunity and inflammation, with complement activation and 
platelet dysfunction, which further enhance the damage [97,99]. Hence, without any safeguard 
mechanisms the combined action of Ang II and ET-1 would render the kidney ischemic and fibrotic in a 
short period of time.  However, both systems can also play a protective role by inducing vasodilation and 
natriuresis and inhibiting fibrosis, either acting directly or through stimulation of NO production.  Ang II 
can raise NO via intra-renal Ang II type 2 (AT2) receptors, while ET-1 does so by activating ETB receptors.  
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Thus, it is conceivable that both ET-1 and Ang II, or at least its protective breakdown product, Ang 1-7 
[100], can also play beneficial effects.  Ang 1-7, which is made from Ang I through ACE2 action, can 
activate eNOS and release of NO via the G-protein-coupled Mas receptor [101].  Notably, Ang II, ET-1, and 
NO all inhibit renin release, perhaps as a feedback mechanism to reduce angiotensin production [102].  
Nonetheless, the importance of these protective mechanisms for different disease conditions remains to 
be fully established because their roles vary under pathological conditions, turning a protective into a 
detrimental mechanism.  For example, the AT2 receptors, commonly regarded as part of the protective 
arm of the RAAS, can mediate vasoconstriction under conditions of excess ROS production [103].  
Similarly, in systemic and pulmonary hypertension the ETB receptors were found to be up-regulated in the 
VSMCs of tunica media, where they can play a pathogenic role [104].  Recent studies have also shown that 
ETB receptors mediate tubulo-interstitial fibrosis and its underlying mechanisms, as discussed below, thus 
further aggravating kidney damage (Figure 4)[95].  Studies also suggest that eNOS, the enzyme 
responsible for NO formation, can be stimulated by AT1 receptor activation, but this effect is probably 
short-lived.  Moreover, a predominant down-regulation of eNOS mediated by the AT1 receptor has also 
been reported [105].  
7. Renal fibrosis in CKD: role of endothelial factors and oxidative stress  
Renal fibrosis, the final common outcome of practically all renal diseases causing CKD, including 
hypertensive nephro-angiosclerosis [106], entails a progressive loss of nephrons and their replacement by 
extracellular matrix ultimately leading to ESRD [106].   Fundamental in this process is EMT which entails 
the loss of epithelial markers by tubular cells and their acquisition of mesenchymal features, alongside 
loss of cell contacts, degradation of cell adhesion molecules, onset of migration properties, and finally 
their transformation into fibroblasts, which synthesize collagen and other extracellular matrix proteins 
[107].  First described in embryo development and cancer, EMT occurs in the kidney and involves 
transformation not only of tubular cells but also of podocytes into myofibroblasts [108]. 
ET-1 was found to induce loss of synaptopodin, a podocyte marker, alongside acquisition of the 
mesenchymal marker α-smooth muscle actin in cultured mouse podocytes [108].  The selective ETA 
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antagonist sitaxentan prevented these changes [108], thus suggesting a role of this receptor subtype in 
glomerular EMT.  However, more recent work in a transgenic rat model of Ang II-dependent hypertension 
and in human renal tubular cells, demonstrated a fundamental role of ET-1, acting via ETB receptors [95]: 
EMT was prevented in vivo by the mixed ETA/ETB receptor antagonist bosentan and in vitro by the 
selective ETB receptor antagonist BQ-788.  Figure 5 summarizes the series of events leading to 
hypertensive nephron-angiosclerosis via EMT and ETB receptor. 
A high level of oxidative stress can also participate in this process: the serum levels of the potent 
antioxidant ascorbic acid are decreased in CKD patients, likely because of malnutrition and hemodialysis 
[109,110].  Moreover, serum total antioxidant power is also blunted, supporting the view that high 
oxidative stress can contribute to blunting NO bioactivity, the main opponent of ET-1, in CKD patients.  In 
keeping with this contention chronic administration of green tea was shown to restore endothelium 
vasodilation through ROS scavenging and to protect from hypertension and kidney damage in a rat model 
of Ang II infusion [111].  Moreover, green tea extracts decreased left ventricular mass and p22phox, a 
marker of oxidative stress, in mononuclear cells of CKD patients despite no decrease in BP [112].  
8. Other endothelial factors in renal vascular remodeling 
Vascular remodeling and endothelial dysfunction are hallmarks of patients with ESRD.  In such patients 
arterial remodeling is related inversely to forearm reactive hyperemia and to serum concentrations of 
markers of endothelial dysfunction [113], suggesting that the latter contributes to vascular changes in 
ESRD patients [113].  In hypertension, renal endothelial cell dysfunction is characterized by a decreased 
release of vasodilatory mediators, such as NO, prostacyclin, and EDHF, and/or an increase in 
vasoconstrictive mediators, such as ET-1, Ang II, and thromboxane A2, as discussed above [19].  This may 
affect matrix metalloproteinases and their inhibitors resulting in changes of the extracellular matrix 
composition, leading to renal vascular remodeling [19].  Therapeutic interventions can modulate the 
synthesis and release of both endothelium-derived relaxing and contracting factors, thus influencing the 
vascular remodeling process [114].   
Environmental risk factors, such as high salt intake and vascular inflammation further promote endothelial 
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dysfunction in the kidney [115,116], causing increased expression of adhesion molecules, activation of 
immune cells, cytokine production, and increased oxidative stress [115–117].  Infiltration of immune cells 
in various organs such as blood vessels, kidney, and perivascular adipose tissue is an important 
component of the inflammatory process leading to CV damage and hypertension [117].  Evidence has 
accumulated on the participation of T lymphocytes in hypertension, particularly through effects on the 
kidney [117].  Once activated, Th1 cells may contribute to BP elevation by affecting the kidney and 
vascular remodeling of blood vessels directly via the effects of the cytokines produced [117].  By contrast, 
T-regulatory cells might protect from BP elevation by acting on similar targets [117].  T-regulatory cells 
and Th1 lymphocyte subtypes also have also opposite effects on endothelial function [117], and on 
microvascular remodeling [118].  An imbalance of T-cell subsets was observed in Ang II-infused 
hypertensive rats with kidney injury [119]. Finally, other possible factors linking endothelial factors and 
vascular morphology include endothelial progenitor cells, which are involved in vascular remodeling and 
repair and are regarded as a novel marker of vessel wall injury in patients with CKD [120]. 
9. Conclusions  
Compelling evidence indicates that the endothelium plays a fundamental role in preserving vascular 
health in practically all organs and the kidney is no exception to this rule.  Given the key roles of the 
glomerular and tubular microvasculature in maintaining renal function, preserving and restoring 
endothelial function and preventing endothelial dysfunction seem to be fundamental for preserving GFR 
and preventing CKD.  The novel knowledge generated on the biology of the endothelium and its derived 
factors has made substantial contributions to understanding the mechanisms of kidney damage in 
cardiovascular and metabolic diseases.  In the companion manuscript (Part II) we specifically examine 
endothelial dysfunction in diabetes, preeclampsia, kidney transplantation and how the improving the 
treatment and prevention of kidney disease, 
Funding sources: 
GPR and TMS were supported by grants from the Ministry of Health (RF2011-02352318) and from the 
University of Padova (DOR1625891/16; DOR1670784/16; BIRD163255/16); MB was supported by the 
17 
Swiss National Science Foundation (grants 108258 and 122504); AHJD and AHvdM were supported by a 
grant from the foundation Lijf en Leven; ND was supported by British Heart Foundation Intermediate 
Clinical Research Fellowship (FS/13/30/29994); DJW was supported by the British Heart Foundation, 
Kidney Research UK and the Wellcome Trust. 
Financial disclosures and competing interest statement 
MB serves as a contultant to AbbVie, Inc. The other Authors have no financial disclosures and competing 
interest statement to declare. 
 
  
18 
 
References 
1  Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative 
risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor 
clusters in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease 
Study 2010. Lancet 2012; 380:2224–2260. 
2  Levin A, Tonelli M, Bonventre J, Coresh J, Donner JA, Fogo AB, et al. Global kidney 
health 2017 and beyond: A roadmap for closing gaps in care, research, and policy. Lancet 
Published Online First: 20 April 2017. doi:10.1016/S0140-6736(17)30788-2  
3  Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis. Lancet 2016; 
388:276–284. 
4  Wilkinson IB, McEniery CM. Arterial stiffness, endothelial function and novel 
pharmacological approaches. Clin Exp Pharmacol Physiol 2004; 31:795–799. 
5  Wilkinson IB, Cockcroft JR, McEniery CM. Aortic stiffness as a cardiovascular risk 
predictor. BMJ 2015; :h3764. 
6  Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, et al. Risk of coronary 
events in people with chronic kidney disease compared with those with diabetes: a 
population-level cohort study. Lancet 2012; 380:807–814. 
7  Navar LG. The role of the kidneys in hypertension. J Clin Hypertens 2005; 7:542–9. 
8  Jr MAG, Garcia-Cardena G. Endothelial Cell Dysfunction and the Pathobiology of 
Atherosclerosis. Circ Res 2016; 118:620–636. 
9  Furchgott RF, Zawadzki J V. The obligatory role of endothelial cells in the relaxation of 
arterial smooth muscle by acetylcholine. Nature 1980; 288:373–376. 
10  Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing 
factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 
1987; 84:9265–9269. 
11  Barton M. The discovery of endothelium-dependent contraction: the legacy of Paul M. 
Vanhoutte. Pharmacol Res 2011; 63:455–462. 
12  Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. Characterization of a coronary 
vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985; 248:C550-C556. 
13  Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel 
potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 
332:411–415. 
14  Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, et al. The 
assessment of endothelial function: from research into clinical practice. Circulation 2012; 
126:753–767. 
15  Tang EH, Vanhoutte PM. Endothelial dysfunction: a strategic target in the treatment of 
hypertension? Pflugers Arch 2010; 459:995–1004. 
16  Feletou M, Kohler R, Vanhoutte PM. Nitric oxide: orchestrator of endothelium-dependent 
responses. Ann Med 2012; 44:694–716. 
17  Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: regulation and action. Pharmacol 
Res 2009; 60:448–460. 
19 
18  Schlaich MP, Schmitt D, Ott C, Schmidt BM, Schmieder RE. Basal nitric oxide synthase 
activity is a major determinant of glomerular haemodynamics in humans. J Hypertens 2008; 
26:110–116. 
19  Ponnuchamy B, Khalil RA. Cellular mediators of renal vascular dysfunction in 
hypertension. Am J Physiol Integr Comp Physiol 2009; 296:R1001-R1018. 
20  Luo R, Zhang W, Zhao C, Zhang Y, Wu H, Jin J, et al. Elevated Endothelial Hypoxia-
Inducible Factor-1alpha Contributes to Glomerular Injury and Promotes Hypertensive 
Chronic Kidney Disease. Hypertension 2015; 66:75–84. 
21  Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species 
produced by macrophage-derived foam cells regulate the activity of vascular matrix 
metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 
1996; 98:2572–2579. 
22  Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the 
renin-angiotensin-aldosterone system. Cardiovasc Res 1999; 43:300–307. 
23  Kitamura K, Tanaka T, Kato J, Ogawa T, Eto T, Tanaka K. Immunoreactive endothelin in 
rat kidney inner medulla: marked decrease in spontaneously hypertensive rats. Biochem 
Biophys Res Commun 1989; 162:38–44. 
24  Bourque SL, Davidge ST, Adams MA. The interaction between endothelin-1 and nitric 
oxide in the vasculature: new perspectives. Am J Physiol Integr Comp Physiol 2011; 
300:R1288-R1295. 
25  Kelland NF, Kuc RE, McLean DL, Azfer A, Bagnall AJ, Gray GA, et al. Endothelial cell-
specific ETB receptor knockout: autoradiographic and histological characterisation and 
crucial role in the clearance of endothelin-1. Can J Physiol Pharmacol 2010; 88:644–651. 
26  Gerstung M, Roth T, Dienes H-P, Licht C, Fries JWU. Endothelin-1 induces NF-kappaB 
via two independent pathways in human renal tubular epithelial cells. Am J Nephrol 2007; 
27:294–300. 
27  Lenoir O, Milon M, Virsolvy A, Hénique C, Schmitt A, Massé J-M, et al. Direct action of 
endothelin-1 on podocytes promotes diabetic glomerulosclerosis. J Am Soc Nephrol 2014; 
25:1050–1062. 
28  Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM. Endothelin-1 increases 
glomerular permeability and inflammation independent of blood pressure in the rat. 
Hypertension 2010; 56:942–949. 
29  Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular 
aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular 
smooth muscle cells. J Biol Chem 1994; 269:24316–24320. 
30  Takeda Y, Miyamori I, Yoneda T, Hatakeyama H, Inaba S, Furukawa K, et al. Regulation 
of aldosterone synthase in human vascular endothelial cells by angiotensin II and 
adrenocorticotropin. J Clin Endocrinol Metab 1996; 81:2797–2800. 
31  Ong GS, Young MJ. Mineralocorticoid regulation of cell function: the role of rapid 
signalling and gene transcription pathways. J Mol Endocrinol 2017; 58:R33–R57. 
32  Davel AP, Anwar IJ, Jaffe IZ. The endothelial mineralocorticoid receptor: mediator of the 
switch from vascular health to disease. Curr Opin Nephrol Hypertens 2017; 26:97–104. 
33  Nishikawa T, Suematsu S, Saito J, Soyama A, Ito H, Kino T, et al. Human renal mesangial 
cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem 
20 
Mol Biol 2005; 96:309–316. 
34  White PC. Aldosterone: direct effects on and production by the heart. J Clin Endocrinol 
Metab 2003; 88:2376–2383. 
35  Slight SH, Ganjam VK, Gomez-Sanchez CE, Zhou MY, Weber KT. High affinity NAD(+)-
dependent 11 beta-hydroxysteroid dehydrogenase in the human heart. J Mol Cell Cardiol 
1996; 28:781–787. 
36  Wendler A, Albrecht C, Wehling M. Nongenomic actions of aldosterone and progesterone 
revisited. Steroids 2012; 77:1002–1006. 
37  Barton M, Meyer MR. Nicolaus Copernicus and the rapid vascular responses to aldosterone. 
Trends Endocrinol Metab 2015; 26:396–398. 
38  Romagni P, Rossi F, Guerrini L, Quirini C, Santiemma V. Aldosterone induces contraction 
of the resistance arteries in man. Atherosclerosis 2003; 166:345–349. 
39  Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F, et al. Nongenomic vascular 
action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14:2255–
2263. 
40  Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. Aldosterone regulates 
vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent 
nitric oxide synthase activation. Circulation 2003; 108:2400–2406. 
41  Schmidt BM, Sammer U, Fleischmann I, Schlaich M, Delles C, Schmieder RE. Rapid 
nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension 2006; 
47:650–655. 
42  Rigiracciolo DC, Scarpelli A, Lappano R, Pisano A, Santolla MF, Avino S, et al. GPER is 
involved in the stimulatory effects of aldosterone in breast cancer cells and breast tumor-
derived endothelial cells. Oncotarget 2016; 7:94–111. 
43  Hall JE, Granger JP, Smith MJ, Premen AJ. Role of renal hemodynamics and arterial 
pressure in aldosterone “escape”. Hypertension 1984; 6:I183-1192. 
44  Iwakura Y, Morimoto R, Kudo M, Ono Y, Takase K, Seiji K, et al. Predictors of decreasing 
glomerular filtration rate and prevalence of chronic kidney disease after treatment of 
primary aldosteronism: renal outcome of 213 cases. J Clin Endocrinol Metab 2014; 
99:1593–1598. 
45  Oberleithner H. Two barriers for sodium in vascular endothelium? Ann Med 2012; 44 Suppl 
1:S143-S148. 
46  Oberleithner H, Ludwig T, Riethmuller C, Hillebrand U, Albermann L, Schafer C, et al. 
Human endothelium: target for aldosterone. Hypertension 2004; 43:952–956. 
47  Kusche-Vihrog K, Jeggle P, Oberleithner H. The role of ENaC in vascular endothelium. 
Pflugers Arch 2014; 466:851–859. 
48  Korte S, Strater AS, Druppel V, Oberleithner H, Jeggle P, Grossmann C, et al. Feedforward 
activation of endothelial ENaC by high sodium. FASEB J 2014; 28:4015–4025. 
49  Paar M, Pavenstädt H, Kusche-Vihrog K, Drüppel V, Oberleithner H, Kliche K. Endothelial 
sodium channels trigger endothelial salt sensitivity with aging. Hypertension 2014; 64:391–
396. 
50  Mueller KB, Bender SB, Hong K, Yang Y, Aronovitz M, Jaisser F, et al. Endothelial 
mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular 
21 
function without modulating blood pressure. Hypertension 2015; 66:988–997. 
51  Amador CA, Bertocchio J-P, Andre-Gregoire G, Placier S, Duong Van Huyen J-P, El 
Moghrabi S, et al. Deletion of mineralocorticoid receptors in smooth muscle cells blunts 
renal vascular resistance following acute cyclosporine administration. Kidney Int 2016; 
89:354–362. 
52  Barrera-Chimal J, Prince S, Fadel F, El Moghrabi S, Warnock DG, Kolkhof P, et al. 
Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a 
Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia. J Am Soc Nephrol 
2016; 27:398–404. 
53  Park JB, Schiffrin EL. ET(A) receptor antagonist prevents blood pressure elevation and 
vascular remodeling in aldosterone-infused rats. Hypertension 2001; 37:1444–1449. 
54  Briet M, Barhoumi T, Mian MOR, Coelho SC, Ouerd S, Rautureau Y, et al. Aldosterone-
induced vascular remodeling and endothelial dysfunction require functional angiotensin 
type 1a receptors. Hypertension 2016; 67:897–905. 
55  Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, et al. T regulatory 
lymphocytes prevent aldosterone-induced vascular injury. Hypertension 2012; 59:324–330. 
56  Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, et al. Renal damage in 
primary aldosteronism: results of the PAPY Study. Hypertension 2006; 48:232–238. 
57  Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, et al. Long-term 
renal outcomes in patients with primary aldosteronism. Jama 2006; 295:2638–2645. 
58  Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal 
vascular tone. Lancet 1994; 344:852–854. 
59  Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, et al. Endothelial 
function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. 
A statement by the Working Group on Endothelins and Endothelial Factors of the European 
Society of Hypertension. J Hypertens 2005; 23:233–246. 
60  Seccia TM, Maniero C, Belloni AS, Guidolin D, Pothen P, Pessina AC, et al. Role of 
angiotensin II, endothelin-1 and L-type calcium channel in the development of glomerular, 
tubulointerstitial and perivascular fibrosis. J Hypertens 2008; 26:2022–2029. 
61  Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol 2005; 43:19–29. 
62  Kohan DE, Inscho EW, Wesson D, Pollock DM. Physiology of endothelin and the kidney. 
Compr Physiol 2011; 1:883–919. 
63  Briet M, Boutouyrie P, Laurent S, London GM. Arterial stiffness and pulse pressure in 
CKD and ESRD. Kidney Int 2012; 82:388–400. 
64  Fortier C, Mac-Way F, Desmeules S, Marquis K, De Serres SA, Lebel M, et al. Aortic-
brachial stiffness mismatch and mortality in dialysis population. Hypertension 2015; 
65:378–384. 
65  Vuurmans TJL, Boer P, Koomans HA. Effects of endothelin-1 and endothelin-1 receptor 
blockade on cardiac output, aortic pressure, and pulse wave velocity in humans. 
Hypertension 2003; 41:1253–1258. 
66  d’Uscio L V, Barton M, Shaw S, Moreau P, Luscher TF. Structure and function of small 
arteries in salt-induced hypertension: effects of chronic endothelin-subtype-A-receptor 
blockade. Hypertension 1997; 30:905–911. 
22 
67  Barton M, d’Uscio L V, Shaw S, Meyer P, Moreau P, Lüscher TF. ET(A) receptor blockade 
prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in 
salt-sensitive hypertension. Hypertension 1998; 31:499–504. 
68  Barton M, Vos I, Shaw S, Boer P, D’Uscio L V, Grone HJ, et al. Dysfunctional renal nitric 
oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery 
endothelial dysfunction and role of endothelin for vascular hypertrophy and 
Glomerulosclerosis. J Am Soc Nephrol 2000; 11:835–845. 
69  Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, et al. 
Endothelin. Pharmacol Rev 2016; 68:357–418. 
70  Dhaun N, Lilitkarntakul P, Macintyre IM, Muilwijk E, Johnston NR, Kluth DC, et al. 
Urinary endothelin-1 in chronic kidney disease and as a marker of disease activity in lupus 
nephritis. Am J Physiol Physiol 2009; 296:F1477-F1483. 
71  Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, et al. Blood 
pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a 
receptor antagonism in chronic kidney disease. Hypertension 2009; 54:113–119. 
72  Goligorsky MS. Pathogenesis of endothelial cell dysfunction in chronic kidney disease: a 
retrospective and what the future may hold. Kidney Res Clin Pract 2015; 34:76–82. 
73  Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S, et al. Selective 
endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness 
in chronic proteinuric kidney disease. Hypertension 2011; 57:772–779. 
74  Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects 
of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and 
nephropathy. N Engl J Med 2001; 345:861–869. 
75  Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective 
effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to 
type 2 diabetes. N Engl J Med 2001; 345:851–860. 
76  Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The 
effect of irbesartan on the development of diabetic nephropathy in patients with type 2 
diabetes. N Engl J Med 2001; 345:870–878. 
77  Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, et al. A selective endothelin-
receptor antagonist to reduce blood pressure in patients with treatment-resistant 
hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374:1423–
1431. 
78  Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, et al. 
Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in 
hypertensive patients with chronic renal failure: a comparison of selective and combined 
endothelin receptor blockade. Circulation 2004; 109:1186–1193. 
79  Vercauteren M, Trensz F, Pasquali A, Cattaneo C, Strasser DS, Hess P, et al. Endothelin 
ETA Receptor Blockade, by Activating ETB Receptors, Increases Vascular Permeability 
and Induces Exaggerated Fluid Retention. J Pharmacol Exp Ther 2017; 361:322–333. 
80  Colombo PC, Ganda A, Lin J, Onat D, Harxhi A, Iyasere JE, et al. Inflammatory activation: 
cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart 
Fail Rev 2012; 17:177–190. 
81  Reitsma S, Slaaf DW, Vink H, van Zandvoort MAMJ, oude Egbrink MGA. The endothelial 
glycocalyx: composition, functions, and visualization. Pflugers Arch 2007; 454:345–359. 
23 
82  Dane MJC, van den Berg BM, Avramut MC, Faas FGA, van der Vlag J, Rops ALWMM, et 
al. Glomerular endothelial surface layer acts as a barrier against albumin filtration. Am J 
Pathol 2013; 182:1532–1540. 
83  Jeansson M, Haraldsson B. Morphological and functional evidence for an important role of 
the endothelial cell glycocalyx in the glomerular barrier. Am J Physiol Renal Physiol 2006; 
290:F111-F116. 
84  Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, et al. Heparanase is 
essential for the development of diabetic nephropathy in mice. Diabetes 2012; 61:208–216. 
85  Harada H, Takahashi M. CD44-dependent intracellular and extracellular catabolism of 
hyaluronic acid by hyaluronidase-1 and -2. J Biol Chem 2007; 282:5597–5607. 
86  Wang L, Fuster M, Sriramarao P, Esko JD. Endothelial heparan sulfate deficiency impairs 
L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. 
Nat Immunol 2005; 6:902–910. 
87  Garsen M, Lenoir O, Rops ALWMM, Dijkman HB, Willemsen B, van Kuppevelt TH, et al. 
Endothelin-1 Induces Proteinuria by Heparanase-Mediated Disruption of the Glomerular 
Glycocalyx. J Am Soc Nephrol 2016; 27:3545–3551. 
88  van den Hoven MJ, Rops AL, Bakker MA, Aten J, Rutjes N, Roestenberg P, et al. Increased 
expression of heparanase in overt diabetic nephropathy. Kidney Int 2006; 70:2100–2108. 
89  Oberleithner H, Peters W, Kusche-Vihrog K, Korte S, Schillers H, Kliche K, et al. Salt 
overload damages the glycocalyx sodium barrier of vascular endothelium. Pflugers Arch 
2011; 462:519–528. 
90  Rossi GP, Seccia TM, Nussdorfer GG. Reciprocal regulation of endothelin-1 and nitric 
oxide: relevance in the physiology and pathology of the cardiovascular system. Int Rev 
Cytol 2001; 209:241–272. 
91  Barton M, Shaw S, d’Uscio L V, Moreau P, Luscher TF. Angiotensin II increases vascular 
and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of 
ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997; 238:861–
865. 
92  Lin YJ, Kwok CF, Juan CC, Hsu YP, Shih KC, Chen CC, et al. Angiotensin II enhances 
endothelin-1-induced vasoconstriction through upregulating endothelin type A receptor. 
Biochem Biophys Res Commun 2014; 451:263–269. 
93  Kawaguchi H, Sawa H, Yasuda H. Effect of endothelin on angiotensin converting enzyme 
activity in cultured pulmonary artery endothelial cells. J Hypertens 1991; 9:171–174. 
94  Rossi GP, Ganzaroli C, Cesari M, Maresca A, Plebani M, Nussdorfer GG, et al. Endothelin 
receptor blockade lowers plasma aldosterone levels via different mechanisms in primary 
aldosteronism and high-to-normal renin hypertension. Cardiovasc Res 2003; 57:277–283. 
95  Seccia TM, Caroccia B, Gioco F, Piazza M, Buccella V, Guidolin D, et al. Endothelin-1 
drives epithelial-mesenchymal transition in hypertensivenNephroangiosclerosis. J Am Heart 
Assoc 2016; 5:10.1161/JAHA.116.003888. 
96  Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M, Kalluri R. Fibroblasts in kidney 
fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008; 
19:2282–2287. 
97  Barton M. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat 
Clin Pract 2008; 4:490–501. 
24 
98  Barton M. Therapeutic potential of endothelin receptor antagonists for chronic proteinuric 
renal disease in humans. Biochim Biophys Acta 2010; 1802:1203–1213. 
99  Barton M. Prevention and endothelial therapy of coronary artery disease. Curr Opin 
Pharmacol 2013; 13:226–241. 
100  Unger T. The Protective Arm of the Renin Angiotensin System (RAS). 1st Edition. Academic 
Press; 2015.  
101  van Twist DJ, Kroon AA, de Leeuw PW. Angiotensin-(1-7) as a strategy in the treatment of 
hypertension? Curr Opin Nephrol Hypertens 2014; 23:480–486. 
102  Kurtz A, Wagner C. Role of nitric oxide in the control of renin secretion. Am J Physiol 
1998; 275:F849-F862. 
103  Verdonk K, Danser AH, van Esch JH. Angiotensin II type 2 receptor agonists: where should 
they be applied? Expert Opin Investig Drugs 2012; 21:501–513. 
104  Iglarz M, Steiner P, Wanner D, Rey M, Hess P, Clozel M. Vascular Effects of Endothelin 
Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on 
the Functionality of Endothelial ETB Receptors. J Cardiovasc Pharmacol 2015; 66:332–
337. 
105  MacKenzie A. Endothelium-derived vasoactive agents, AT1 receptors and inflammation. 
Pharmacol Ther 2011; 131:187–203. 
106  Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-
stage renal failure. J Am Soc Nephrol 2006; 17:17–25. 
107  Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts 
derive from epithelium during tissue fibrosis. J Clin Invest 2002; 110:341–350. 
108  Buelli S, Rosano L, Gagliardini E, Corna D, Longaretti L, Pezzotta A, et al. Beta-Arrestin-1 
Drives Endothelin-1-Mediated Podocyte Activation and Sustains Renal Injury. J Am Soc 
Nephrol 2014; 25:523–533. 
109  Takahashi N, Morimoto S, Okigaki M, Seo M, Someya K, Morita T, et al. Decreased 
plasma level of vitamin C in chronic kidney disease: comparison between diabetic and non-
diabetic patients. Nephrol Dial Transplant 2011; 26:1252–1257. 
110  Locatelli F, Canaud B, Eckardt K-U, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress 
in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 
2003; 18:1272–1280. 
111  Antonello M, Montemurro D, Bolognesi M, Di Pascoli M, Piva A, Grego F, et al. 
Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green 
tea extracts. Am J Hypertens 2007; 20:1321–1328. 
112  Calo LA, Vertolli U, Davis PA, Maso LD, Pagnin E, Ravarotto V, et al. Molecular biology 
based assessment of green tea effects on oxidative stress and cardiac remodelling in dialysis 
patients. Clin Nutr 2014; 33:437–442. 
113  Pannier B, Guerin AP, Marchais SJ, Metivier F, Safar ME, London GM. Postischemic 
vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal 
disease. Kidney Int 2000; 57:1091–1099. 
114  Raij L. Mechanisms of vascular injury: the emerging role of the endothelium. J Am Soc 
Nephrol 1991; 2:S2-S8. 
115  Montezano AC, Touyz RM. Molecular mechanisms of hypertension--reactive oxygen 
25 
species and antioxidants: a basic science update for the clinician. Can J Cardiol 2012; 
28:288–295. 
116  Sinha N, Dabla PK. Oxidative stress and antioxidants in hypertension-a current review. 
Curr Hypertens Rev 2015; 11:132–142. 
117  Ciuceis C De, Rossini C, Boria E La, Porteri E, Petroboni B, Gavazzi A, et al. Immune 
mechanisms in hypertension. High Blood Press Cardiovasc Prev 2014; 21:227–234. 
118  Ciuceis C De, Rossini C, Airo P, Scarsi M, Tincani A, Tiberio GA, et al. Relationship 
Between Different Subpopulations of Circulating CD4+ T-lymphocytes and Microvascular 
Structural Alterations in Humans. Am J Hypertens 2017; 30:51–60. 
119  Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, et al. Imbalance of T-cell 
subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003; 
42:31–38. 
120  Rabelink TJ, de Boer HC, van Zonneveld AJ. Endothelial activation and circulating markers 
of endothelial activation in kidney disease. Nat Rev 2010; 6:404–414. 
  
26 
 
Legends to the Figures 
Figure 1. Endothelium-derived factors inducing relaxation / growth inhibition and contraction / cell 
proliferation of vascular smooth muscle cells (VSMCs).  Vasodilatating factors include nitric oxide (NO), 
PGI2 and endothelium derived hyperpolarization (EDH), whereas contracting factors include endothelin-1 
(ET-1) and endothelium-derived contracting factors (EDCF), including thromboxane A2 and prostaglandin 
H2.  Shear stress, acetylcholine and bradykinin activate endothelial nitric oxide synthase (eNOS), which 
generates the soluble gas NO that, after diffusing through the cell membranes of endothelial and VSMCs, 
binds the soluble guanylate cyclase (sGC). This latter synthesizes cyclic guanosine monophosphate (cGMP) 
from guanosine-5'-triphosphate (GTP), thereby inducing VSMC relaxation. In contrast, relaxation triggered 
by EDHF is mostly mediated by activation of K+ channels and blunting of Ca2+ channels activity, which 
cause cell hyperpolarization.   
ET-1 is generated from big ET-1 via two endothelin converting enzyme (ECE) isoforms, ECE-1 and ECE-2.  In 
VSMC ET-1 exerts contracting and growth-promoting effects primarirly via ETA (and in some vascular beds 
also via ETB receptors), whereas, when it binds ETB receptors in endothelial cells, activates eNOS leading to 
NO production, finally inducing relaxation. TXA2 and Ang II cause VSMCs contraction and proliferation via 
TP and AT1 receptors, respectively.  
Under physiological condition, a balance between relaxation and contraction allows maintenance of 
vascular tone. Excess production of Ang II and cytokines, or release of reactive oxygen species (ROS) 
during inflammation and hypoxia, favor production of ET-1 and hypoxia-induced factor (HIF) along a 
decrease of NO, thereby causing an unbalanced vasoconstriction.  Excess mechanical stress, as well as 
cardiovascular (CV) risk factors, as aging, smoking, hypercholesterolemia, diabetes mellitus, and 
hyperhomocysteinemia, also favor production of ROS, particularly superoxide anion (°O2- ), which by 
reacting with NO at a diffusion limited rate (6.7 x 109 x sec-1) to form the stable peroxynitrite (ONOO.), 
thereby inactivating NO.  ADMA also decreases NO bioavailability and activate metalloproteases (MMPs) 
27 
that, in turn, induce ONOO. production in mononuclear cells, finally amplifying inflammation and leading 
microcirculatory dysfunction and plaque destabilization. 
Figure 2. Schematic representation of the actions and interactions of ET-1 (blue) between glomerular 
capillary basement membrane (GBM, grey), glomerular endothelial cells (GEC, yellow), glomerular 
podocytes (green/yellowish), and the slit diaphragm (red). Shown are mechanisms (1-7) which implicate 
endothelial-cell derived ET-1 in podocyte and glomerular injury. ET-1 is released from cells on both sides 
of the GBM, namely glomerular endothelial cells (GEC) and podocytes. ET-1 interacts with different 
cellular components of the glomerular capillary: ET-1 released from GEC interacts with the GBM (1), with 
the slit diaphragm (2), or with the podocyte (3). ET-1 release and signaling may also occur in the reverse 
direction. Accordingly, ET-1 released from podocytes may interact with the GBM and vice versa (4). Within 
the podocyte, ET-1 activates endothelin ETA receptors (ETA–R) and promotes glomerular cell injury and 
sclerosis through MAPKs p38 and p44/p42 pathways (5); moreover, ET-1stimulates growth promoter and 
cyclin-dependent kinase-inhibitor p21waf/cip1, and pro-inflammatory NF-kappa B (6). ET-1 also causes F-
actin cytoskeleton dysruption (7) and thus slit diaphragm dysfunction (green) involving activation of the 
Rho-kinase and PI3-kinase pathways. Figure reproduced with permission from Barton M. Therapeutic 
potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans. BBA 
Molecular Basis of Disease 2010. 
Figure 3. Effects of the renin-angiotensin aldosterone system (RAAS) and the endothelin-1 (ET-1) system 
in the kidney. Under physiological conditions Angiotensin II (Ang II) maintains glomerular filtration rate by 
modulating the efferent arteriole tone, and regulates blood volume by stimulating water and Na+ 
absorption in the distal and collecting tubules, both directly and indirectly via aldosterone production.  
Pathophysiological conditions as aging, hyperglycemia, hypoxia and inflammation, characterized by 
release of reactive oxygen species (ROS) and cytokines, cause excess Ang II and ET-1 synthesis. In addition, 
Ang II stimulates ET-1 synthesis. This translates into constriction of both afferent and efferent arterioles 
with reduced glomerular filtration rate (GFR), and also into reduction of NO. bioavailability that causes 
renin release from juxtaglomerular cells, finally leading to amplification of the RAAS activity.  
28 
Figure 4. Relationship between the renin angiotensin aldosterone system (RAAS) and the endothelin-1 
(ET-1) system in the glomerulus. Under physiological conditions Angiotensin II (Ang II), via AT1 receptors, 
regulates the glomerular capillary tone, podocyte function and mesangial cell contraction.  
Pathophysiological conditions characterized by excess release of reactive oxygen species (ROS) and pro-
inflammatory cytokines cause excess Ang II and ET-1 synthesis. Both excess Ang II and ET-1 induce, via AT1 
and ETA receptors respectively, 1) endothelial damage and podocyte injury, which both cause proteinuria, 
2) proliferation of the mesangial cells and extracellular matrix production, 3) epithelial to mesenchymal 
transition finally leading to glomerular sclerosis and fibrosis. 
Figure 5. Effects of the renin angiotensin aldosterone system (RAAS) and the endothelin-1 (ET-1) system in 
the tubulo-interstitial compartment. Under physiological conditions both Angiotensin II (Ang II) and 
endothelin-1 (ET-1) maintain the vascular tone: AT1, ETA and ETB receptor subtypes located at the vascular 
smooth muscle cells (VSMCs) mediate vasoconstriction, whereas ETB receptor subtype located at the 
endothelial cells, by increasing NO. bioavailability, mediates vasodilatation.  ETB receptor also exerts a 
crucial role by regulating water excretion at the tubular level. When Ang II is abnormally produced, as 
under conditions characterized by excess mechanical or oxidative stress (e.g. diabetes mellitus, high blood 
pressure, hypercholesterolemia), AT1 receptors in the VSMCs favor vasoconstriction and vascular 
remodeling. Excess Ang II also stimulates ET-1 production that, via ETA and ETB located at the VSMCs, 
potentiates vasoconstriction, and, via ETB receptor subtype, triggers epithelial to mesenchymal transition 
(EMT), transforming the tubular cells into myofibroblasts that produce collagens, finally leading to tubulo-
interstitial fibrosis. 
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